Published Online
on October 28, 2002

A more recent version of this article appeared on November 19, 2002

This Article Full Text (PDF) All Versions of this Article: 106/21/2694    most recent 01.CIR.0000038499.22687.39v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellison, K. E. Search for Related Content PubMed PubMed Citation Articles by Ellison, K. E. Related Collections Arrhythmias, clinical electrophysiology, drugs Chronic ischemic heart disease Ablation/ICD/surgery

Submitted on June 10, 2002
Revised on August 28, 2002
Accepted on September 2, 2002

Effect of ß-Blocking Therapy on Outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT)

Kristin E. Ellison MD^*, Gail E. Hafley MS, Kathleen Hickey ANP-C, Joyce Kellen MSc, James Coromilas MD, Kenneth M. Stein MD, Kerry L. Lee PhD, Alfred E. Buxton MD, and for the MUSTT Investigators

From Brown Medical School (K.E.E., A.E.B.), Providence, RI; Duke Clinical Research Institute (G.E.H., K.L.L.), Durham, NC; Columbia University Medical Center (K.H., J.C.), New York, NY; University of Calgary (J.K.), Calgary, Alberta, Canada; and Cornell Medical Center (K.M.S.), New York, NY.

^* To whom correspondence should be addressed. E-mail: kellison{at}lifespan.org.

Background—ß-Blockers are known to reduce total mortality and sudden death in survivors of recent myocardial infarction. The effects of these agents in patients at high risk for sudden death with remote infarction are not clear.

Methods and Results—We analyzed the effect of ß-blockers on outcomes in 2096 patients with coronary artery disease, ejection fraction 40%, and spontaneous nonsustained ventricular tachycardia enrolled in the Multicenter UnSustained Tachycardia Trial (MUSTT). Forty-five percent of 702 patients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients without inducible tachycardia were discharged from hospital receiving ß-blockers. Patients treated with ß-blockers were younger and had higher ejection fractions, higher rates of recent angina, and more recent infarction. ß-Blockers were associated with decreased total mortality for the entire study population (5-year mortality 50% with ß-blockers versus 66% without ß-blockers; adjusted P=0.0001). The mortality benefit associated with ß-blockers was present in patients with and without inducible tachycardia, except those treated with implantable defibrillators. There was no significant effect of ß-blocker therapy on the rate of arrhythmic death or cardiac arrest (adjusted P=0.2344).

Conclusions—ß-Blocking agents have beneficial effects on survival of patients having characteristics of those enrolled in the MUSTT trial. These effects do not appear to be due to a specific antiarrhythmic effect of ß-blockers. The beneficial effects of ß-blockers were demonstrable in all patients except those treated with implantable defibrillators.

Key words: death, sudden • beta-blocker • myocardial infarction • implantable cardioverter defibrillator

This article has been cited by other articles:

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1064 - 1108. [Full Text] [PDF]

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]

				D. P. Zipes, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart J., September 1, 2006; 27(17): 2099 - 2140. [Full Text] [PDF]

				Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]

				J. P. Singh, W. J. Hall, S. McNitt, H. Wang, J. P. Daubert, W. Zareba, J. N. Ruskin, A. J. Moss, and and the MADIT-II Investigators Factors Influencing Appropriate Firing of the Implanted Defibrillator for Ventricular Tachycardia/Fibrillation: Findings From the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1712 - 1720. [Abstract] [Full Text] [PDF]

				J. A. Reiffel Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S45 - S58. [Abstract] [PDF]

				H. Lorenz, C. Junger, K. Seidl, A. Gitt, S. Schneider, R. Schiele, H. Wienbergen, R. Winkler, M. Gottwik, W. Delius, et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur. Heart J., June 1, 2005; 26(11): 1078 - 1085. [Abstract] [Full Text] [PDF]